Puma Biotechnology, Inc. [PBYI] moving up 2.36% What are the long-term prospects? – The Dwinnex

Puma Biotechnology, Inc. [PBYI] is following upward trend in the market concluded with the last trading session. The shares of the Healthcare sector company has a current value of $9.96 after PBYI shares went up by 2.36% during the last trading session. One of the reasons why Healthcare stocks may go bullish is increased momentum in the press.

Its stock price has been found in the range of 6.26 to 43.90. This is compared to its latest closing price of $9.73.

Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on Thu 27 Feb (In 37 Days).

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology, Inc. [PBYI] sitting at -37.72 and its Gross Margin at +86.21, this companys Net Margin is now -33.90%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -65.75, and its Return on Invested Capital has reached -55.70%. Its Return on Equity is -259.28, and its Return on Assets is -53.49. These metrics suggest that this Puma Biotechnology, Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology, Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 442.74. Similarly, its Total Debt to Total Capital is 81.57, while its Total Debt

What about valuation? This companys Enterprise Value to EBITDA is -3.57. The Enterprise Value to Sales for this firm is now 1.11, and its Total Debt to Enterprise Value stands at 0.20. Puma Biotechnology, Inc. [PBYI] has a Price to Book Ratio of 22.73.

Shifting the focus to workforce efficiency, Puma Biotechnology, Inc. [PBYI] earns $922,761 for each employee under its payroll. Similarly, this companys Receivables Turnover is 15.88 and its Total Asset Turnover is 1.18. This publicly-traded organizations liquidity data is also interesting: its Quick Ratio is 2.99 and its Current Ratio is 3.02. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Puma Biotechnology, Inc. [PBYI] has 36.62M shares outstanding, amounting to a total market cap of $356.31M. Its stock price has been found in the range of 6.26 to 43.90. At its current price, it has moved down by -77.31% from its 52-week high, and it has moved up 59.11% from its 52-week low.

This stocks Beta value is currently 1.73, which indicates that it is 10.35% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 61.95. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology, Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

Original post:
Puma Biotechnology, Inc. [PBYI] moving up 2.36% What are the long-term prospects? - The Dwinnex